 |
|
CLINICIAN'S CORNER
Nonhormonal Therapies for Menopausal Hot Flashes
Systematic Review and Meta-analysis
Heidi D. Nelson, MD, MPH;
Kimberly K. Vesco, MD;
Elizabeth Haney, MD;
Rongwei Fu, PhD;
Anne Nedrow, MD;
Jill Miller, MD;
Christina Nicolaidis, MD, MPH;
Miranda Walker, BA;
Linda Humphrey, MD, MPH
JAMA. 2006;295:2057-2071.
Context Concern regarding the adverse effects of estrogen and other hormones for treating menopausal symptoms has led to demand for other options; however, the efficacy and adverse effects of nonhormonal therapies are unclear.
Objective To assess the efficacy and adverse effects of nonhormonal therapies for menopausal hot flashes by reviewing published randomized controlled trials.
Data Sources MEDLINE (1966-October 2005), PsycINFO (1974-October 2005), and the Cochrane Controlled Clinical Trials Register Database (1966-October 2005) were searched for relevant trials that provided data on treatment of menopausal hot flashes using 1 or more nonhormonal therapies.
Study Selection All English-language, published, randomized, double-blind, placebo-controlled trials of oral nonhormonal therapies for treating hot flashes in menopausal women measuring and reporting hot flash frequency or severity outcomes.
Data Extraction Trials were identified, subjected to inclusion and exclusion criteria, and reviewed. Data on participants, interventions, and outcomes were extracted and trials were rated for quality based on established criteria. A meta-analysis was conducted for therapies with sufficient trials reporting hot flash frequency outcomes.
Data Synthesis From 4249 abstracts, 43 trials met inclusion criteria, including 10 trials of antidepressants, 10 trials of clonidine, 6 trials of other prescribed medications, and 17 trials of isoflavone extracts. The number of daily hot flashes decreased compared with placebo in meta-analyses of 7 comparisons of selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) (mean difference, –1.13; 95% confidence interval [CI], –1.70 to –0.57), 4 trials of clonidine (–0.95; 95% CI, –1.44 to –0.47), and 2 trials of gabapentin (–2.05; 95% CI, –2.80 to –1.30). Frequency was not reduced in meta-analysis of trials of red clover isoflavone extracts and results were mixed for soy isoflavone extracts. Evidence of the efficacy of other therapies is limited due to the small number of trials and their deficiencies. Trials do not compare different therapies head-to-head and relative efficacy cannot be determined.
Conclusion The SSRIs or SNRIs, clonidine, and gabapentin trials provide evidence for efficacy; however, effects are less than for estrogen, few trials have been published and most have methodological deficiencies, generalizability is limited, and adverse effects and cost may restrict use for many women. These therapies may be most useful for highly symptomatic women who cannot take estrogen but are not optimal choices for most women.
Author Affiliations: Oregon Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology (Drs Nelson, Vesco, Haney, Fu, Nedrow, Miller, Nicolaidis, and Humphrey, and Ms Walker), Department of Medicine (Drs Nelson, Haney, Nedrow, Miller, Nicolaidis, and Humphrey), Department of Public Health and Preventive Medicine (Drs Fu, Nicolaidis, and Humphrey), Department of Emergency Medicine (Dr Fu), and Center for Women's Health (Drs Nedrow and Miller), Oregon Health and Science University; Hospital and Specialty Medicine, Veterans Affairs Medical Center (Drs Vesco and Humphrey); and Women and Children's Health Research Center, Providence Health System (Dr Nelson), Portland, Ore.
RELATED ARTICLE
Alternatives to Estrogen for Treatment of Hot Flashes: Are They Effective and Safe?
Jeffrey A. Tice and Deborah Grady
JAMA. 2006;295(17):2076-2078.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer
Powles et al.
Menopause Int 2008;14:6-12.
ABSTRACT
| FULL TEXT
Efficacy and Tolerability of Desvenlafaxine Succinate Treatment for Menopausal Vasomotor Symptoms: A Randomized Controlled Trial
Speroff et al.
Obstet Gynecol 2008;111:77-87.
ABSTRACT
| FULL TEXT
Flash Points
Carpenter and Flockhart
JCO 2007;25:5546-5547.
FULL TEXT
Randomized, Controlled Trial of Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients
Deng et al.
JCO 2007;25:5584-5590.
ABSTRACT
| FULL TEXT
Implications of Phytoestrogen Intake for Breast Cancer
Duffy et al.
CA Cancer J Clin 2007;57:260-277.
ABSTRACT
| FULL TEXT
Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists
Collins et al.
Eur Heart J 2007;28:2028-2040.
ABSTRACT
| FULL TEXT
Possible Increase in Liver Enzymes Secondary to Atorvastatin and Black Cohosh Administration
Patel and Derkits
Journal of Pharmacy Practice 2007;20:341-346.
ABSTRACT
Risk-Reducing Salpingo-Oophorectomy in Patients With Germline Mutations in BRCA1 or BRCA2
Kauff and Barakat
JCO 2007;25:2921-2927.
ABSTRACT
| FULL TEXT
Managing the menopause
Roberts
BMJ 2007;334:736-741.
FULL TEXT
Randomized, Double-Blind, Placebo-Controlled Crossover Trials of Venlafaxine for Hot Flashes After Breast Cancer
Carpenter et al.
The Oncologist 2007;12:124-135.
ABSTRACT
| FULL TEXT
A Randomized Trial of Alternative Medicines for Vasomotor Symptoms of Menopause
Mangione
ANN INTERN MED 2006;145:924-925.
FULL TEXT
Influence of Hormone Replacement Therapy on Tamoxifen-Induced Vasomotor Symptoms
Sestak et al.
JCO 2006;24:3991-3996.
ABSTRACT
| FULL TEXT
Alternative Nonhormonal Therapies Are of Modest Value for Hot Flashes
JWatch General 2006;2006:4-4.
FULL TEXT
What's new in the other general journals.
Tonks
BMJ 2006;332:1146-1147.
FULL TEXT
Alternatives to estrogen for treatment of hot flashes: are they effective and safe?
Tice and Grady
JAMA 2006;295:2076-2078.
FULL TEXT
|
